Edition:
United States

Biotest AG (BIOG.DE)

BIOG.DE on Xetra

27.25EUR
26 May 2017
Change (% chg)

€-0.02 (-0.07%)
Prev Close
€27.27
Open
€27.11
Day's High
€27.44
Day's Low
€27.11
Volume
9,244
Avg. Vol
35,943
52-wk High
€28.60
52-wk Low
€15.44

Latest Key Developments (Source: Significant Developments)

Public cash offer for Biotest shares launched
Thursday, 18 May 2017 01:58am EDT 

May 18 (Reuters) - Tiancheng (Germany) Pharmaceutical Holdings Ag, A Company Indirectly Controlled By Creat Group Corporation Says Has Launched Public Cash Offer For Biotest Ag :.  Full Article

Biotest opens seventh plasma collection centre in Hungary
Tuesday, 16 May 2017 01:00am EDT 

May 16 (Reuters) - BIOTEST AG ::OPENS SEVENTH PLASMA COLLECTION CENTRE IN HUNGARY.  Full Article

Biotest reports Q1 revenue of EUR 110 mln
Wednesday, 10 May 2017 01:00am EDT 

May 10 (Reuters) - BIOTEST AG ::BIOTEST REPORTS REVENUE OF EUR 110 MILLION IN THE FIRST QUARTER 2017.EBIT OF CONTINUING OPERATIONS AMOUNTED TO EUR -24.9 MILLION IN Q1 OF 2017 COMPARED TO PREVIOUS YEAR'S FIGURE OF EUR 17.0 MILLION.IN FIRST THREE MONTHS OF 2017 FINANCIAL YEAR, EARNINGS AFTER TAXES OF CONTINUING OPERATIONS IN AMOUNT OF EUR -16.7 MILLION (SAME PERIOD OF PREVIOUS YEAR: EUR 10.3 MILLION).2017 GUIDANCE FOR EBIT OF CONTINUING OPERATIONS OF EUR 46 MILLION TO EUR 48 MILLION HAS BEEN REDUCED BY AROUND EUR 25 MILLION TO EUR 30 MILLION..FORECASTING 2017 SALES AT PREVIOUS YEAR'S LEVEL FOR CONTINUING OPERATIONS IN 2017, AFTER PREVIOUSLY HAVING FORECAST A LOW SINGLE-DIGIT PERCENTAGE INCREASE IN SALES.  Full Article

Biotest recalls human albumin and reduces forecast
Wednesday, 26 Apr 2017 11:43am EDT 

April 26 (Reuters) - Biotest AG ::Recalls human albumin and reduces forecast.Performed a batch recall of human albumin (Albiomin(R)) 5 percent and 20 percent Biotest injection solution.Batches in question had already been quarantined by Biotest on April 13, 2017.As a precautionary measure, reduces its sales guidance from single-digit growth rate to level of previous year and its EBIT guidance of 46 million euros to 48 million euros ($49.95 million - $52.12 million) by 25 million to 30 million euros.  Full Article

Biotest opens sixth plasma collection centre in Hungary
Wednesday, 19 Apr 2017 01:00am EDT 

April 19 (Reuters) - Biotest Ag ::Opens sixth plasma collection centre in Hungary.  Full Article

Biotest informs about limited availability of albumin
Thursday, 13 Apr 2017 11:37am EDT 

Biotest AG : Biotest informs about limited availability of albumin . Due to an equipment failure the availability of albumin is currently limited .Consequences on sales and annual results are currently not assessable.  Full Article

Biotest comments on Business Combination Agreement with Creat
Friday, 7 Apr 2017 06:40am EDT 

Biotest AG : Biotest AG, Tiancheng International Investment Limited, Hong Kong, and Blitz 17-623 AG (in future: Tiancheng (Germany) Pharmaceutical Holdings AG), affiliated companies controlled by Creat Group Corporation, have signed a Business Combination Agreement today . Management board and supervisory board welcome and support takeover offer .Biotest and Creat view transaction as an opportunity to further develop company.  Full Article

Biotest says Chinese investor Creat to make voluntary public takeover offer
Friday, 7 Apr 2017 06:36am EDT 

Biotest AG : Chinese strategic investor Creat to make a voluntary public takeover offer for the shares of Biotest AG . Tiancheng (Germany) Pharmaceutical Holdings AG announced its decision to make a voluntary public takeover offer for all outstanding ordinary and preference shares of Biotest AG . Offer will be subject to a minimum acceptance threshold of 75 percent of all ordinary shares as well as regulatory approvals . To offer for all outstanding ordinary and preference shares of Biotest AG for 28.50 euros ($30.30) per ordinary share and 19.00 euros per preference share in an all-cash transaction .Biotest was informed that Biotest AG's majority shareholder, Ogel GmBH, supports transaction.  Full Article

Biotest: discussions regarding business combination
Thursday, 30 Mar 2017 02:10am EDT 

Biotest AG : Said on Wednesday: Biotest Aktiengesellschaft and creat group corporation are currently in discussions regarding a potential business combination . Biotest ag - Creat Group indicated key parameters of potential combination to be through public tender offer for all common and preference shares of Biotest . Biotest AG - consideration is 28.50 euros ($30.65) per ordinary share and 19 euros per preference share of Biotest aktiengesellschaft .Biotest - potential transaction is subject to final negotiations of business combination agreement and agreement with co's majority shareholder OGEL.  Full Article

Biotest: discussions regarding business combination
Wednesday, 29 Mar 2017 05:29pm EDT 

Biotest AG : Said on Wednesday: Biotest Aktiengesellschaft and creat group corporation are currently in discussions regarding a potential business combination . Biotest ag - Creat Group indicated key parameters of potential combination to be through public tender offer for all common and preference shares of Biotest . Biotest AG - consideration is 28.50 euros ($30.65) per ordinary share and 19 euros per preference share of Biotest aktiengesellschaft .Biotest - potential transaction is subject to final negotiations of business combination agreement and agreement with co's majority shareholder OGEL.  Full Article

More From Around the Web

BRIEF-Public cash offer for Biotest shares launched

May 18 Tiancheng (Germany) Pharmaceutical Holdings Ag, A Company Indirectly Controlled By Creat Group Corporation Says Has Launched Public Cash Offer For Biotest Ag